Neoplasms

Respiratory Tract (Lung and Bronchial) Diseases

All Conditions

Skin and Connective Tissue Diseases

Symptoms and General Pathology

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Gland and Hormone Related Diseases

Rare Diseases

Carcinoma, Non-Small-Cell Lung

Breast Neoplasms

Neoplasm Metastasis

Lung Neoplasms

Ovarian Neoplasms

Carcinoma, Ovarian Epithelial

Endocrine Gland Neoplasms

Ovarian Diseases

Adnexal Diseases

Genital Diseases, Female

Genital Diseases

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Genital Neoplasms, Female

Urogenital Neoplasms

Endocrine System Diseases

Gonadal Disorders

Ovarian Cancer

Ovarian Epithelial Cancer

All Drugs and Chemicals

Antibodies

Immunomodulating Agents

Immunoglobulins

Phase 1 Dose Escalation (Cohort 1): Subjects received NC762 IV at 0.5mg/kg Q2W until disease progression, withdraw of consent, or intolerable toxicity (whichever comes first).

Phase 1 Dose Escalation (Cohort 2): Subjects received NC762 IV at 1.5mg/kg Q2W until disease progression, withdraw of consent, or intolerable toxicity (whichever comes first).

Phase 1 Dose Escalation (Cohort 3): Subjects received NC762 IV at 5mg/kg Q2W until disease progression, withdraw of consent, or intolerable toxicity (whichever comes first).

Phase 1 Dose Escalation (Cohort 4): Subjects received NC762 IV at 10mg/kg Q2W until disease progression, withdraw of consent, or intolerable toxicity (whichever comes first).

Phase 1 Dose Escalation (Cohort 5): Subjects received NC762 IV at 20mg/kg Q2W until disease progression, withdraw of consent, or intolerable toxicity (whichever comes first).

NC762 is an experimental antibody drug that may make the immune response more active against cancer

NC762

Han Myint, MD

This research study is studying a new drug, NC762, as a possible treatment for advanced or metastatic solid tumors.

Phase 1 will utilize a 3 + 3 design to explore escalating dose levels. Phase 2 Dose Expansion will further evaluate the safety, tolerability, preliminary efficacy, and PK/PD activity of NC762 at the RP2D utilizing a Simon 2-stage design.

A Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors

A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors

Frequency, duration, and severity of treatment-emergent adverse events (AEs)

A 3 + 3 design will be utilized to determine the MTD of NC762

Objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and modified RECIST(mRECIST) v1.1

Duration of Response (DoR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and modified RECIST (mRECIST) v1.1

Disease Control Rate (DCR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and modified RECIST (mRECIST) v1.1

To evaluate the Maximum Plasma Concentration (Cmax) of NC762

To evaluate downregulation of B7-H4 expression and changes in tumor infiltrating lymphocytes after NC762 treatment.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
A Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors	NCT04875806	Advanced or Met... Ovarian Cancer Non-small Cell ... Breast Cancer	NC762	18 Years -	NextCure, Inc.
A Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors	NCT04875806	Advanced or Met... Ovarian Cancer Non-small Cell ... Breast Cancer	NC762	18 Years -	NextCure, Inc.

Spots Global Cancer Trial Database for nc762

Every month we try and update this database with for nc762 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for nc762

Every month we try and update this database with for nc762 cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for nc762 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.